Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa - 23/11/17
Abstract |
Background |
Psoriasis and hidradenitis suppurativa (HS) exhibit distinct clinical features, but no studies have directly compared the health-related quality of life (HRQoL) in patients with moderate-to-severe manifestations of these conditions.
Objective |
To determine which disease is associated with more severe HRQoL impairment.
Methods |
Weighted averages of each of the following baseline HRQoL measures were determined and compared between HS and psoriasis populations from 5 clinical trials: Visual Analog Scale (VAS) for pain, Total Work Productivity Impairment, Dermatology Life Quality Index; EuroQOL 5D VAS, and Short Form-36 Health Survey.
Results |
Compared with patients with psoriasis, patients with HS reported higher scores for VAS-pain (54.3 vs 36.1 [P < .0001]), Dermatology Life Quality Index (15.3 vs 11.3 [P < .0001]), EuroQOL 5D VAS (58.8 vs 50.8 [P < .0002]), and Total Work Productivity Impairment (35.4 vs 18.2). Patients with HS had lower Short Form-36 Health Survey scores than did patients with psoriasis (physical, 39.6 vs 49.0; mental, 41.5 vs 47.5 [both P < .0001]).
Limitations |
This analysis was performed using published summary data rather than patient-level data, and weighted pooled averages were compared.
Conclusions |
Patients with HS have a higher HRQoL burden than patients with psoriasis. This study clearly documents the needs of patients with HS and the potential impact of medical, scientific, and societal consensus for the development of more effective HS treatments.
Le texte complet de cet article est disponible en PDF.Key Words : burden, DLQI, EQ-5D VAS, hidradenitis suppurativa, psoriasis, quality of life, SF-36, TWPI, VAS-pain
Abbreviations used : DLQI, EQ-5D, HRQoL, HS, MCS, PCS, SD, SF-36, TWPI, VAS-pain, WPAI
Plan
Design, study conduct, and financial support for the study were provided by AbbVie Inc, which participated in interpretation of the data and review and approval of the manuscript. All authors contributed to the development of the publication and maintained control over the final content. |
|
Disclosure: Dr Hamzavi has served or currently serves as an investigator in clinical trial activities for AbbVie Inc, Adelphi Values, and The Microdermis Corporation, with research grants paid to his institution, and he is also the current president of the Hidradenitis Suppurativa Foundation in a nonfunded position. Drs Arikian, Zivkovic, and Lee and Ms Yi have current consulting agreements with AbbVie Inc. Dr Okun is a consultant to United BioSource Corporation (UBC), serves on the speaker's bureau for AbbVie Inc, is a former AbbVie employee, and may have owned AbbVie Inc, stock or stock options. Drs Ganguli and Yihua Gu are employees of AbbVie Inc, and may own AbbVie Inc, stock or stock options. Dr Sundaram is a former employee of AbbVie Inc, and may have owned AbbVie Inc stock or stock options. Ms Parks-Miller serves or has served on an advisory board for AbbVie Inc, has a current consulting agreement with AbbVie Inc, receives funding as the national coordinator of advocacy and support for the Hidradenitis Suppurativa Foundation, and is the founding director of Hope for Hidradenitis Suppurativa. Dr Nicholson is a nonfunded committee member for the Hidradenitis Suppurativa Foundation. |
Vol 77 - N° 6
P. 1038-1046 - décembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?